{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:13:00Z","timestamp":1788441180411,"version":"build-2803163510"},"reference-count":31,"publisher":"IMR Press","issue":"8","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Tianjin Natural Science Foundation.","award":["23JCYBJC01880"],"award-info":[{"award-number":["23JCYBJC01880"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Background:Patients with heart failure (HF) following acute anterior ST-segment elevation myocardial infarction (STEMI) are at high risk for adverse ventricular remodeling, and a significant residual risk persists despite optimal guideline-directed medical therapy (GDMT). Although sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors have demonstrated clear benefit in chronic HF, evidence is limited regarding the early initiation of these inhibitors after acute myocardial infarction (MI), particularly in patients with HF complicating anterior wall infarction. Therefore, this study aimed to evaluate the short-term effects of early initiation of the SGLT2 inhibitor (SGLT2i) empagliflozin, when added to standard medical therapy, on cardiac function and safety in patients with HF following acute anterior STEMI.Methods:This single-center retrospective cohort study consecutively enrolled 98 patients hospitalized at Tianjin Union Medical Center between January 2022 and December 2022 with acute anterior STEMI complicated by HF. Patients were divided into two groups based on SGLT2i use: the control group (n = 49) received standard medical therapy alone, while the SGLT2i group (n = 49) received empagliflozin 10 mg once daily in addition to standard therapy. The primary outcome was the change in left ventricular ejection fraction (LVEF) from admission to one month after discharge. Analysis of covariance (ANCOVA) and multivariable linear regression models were employed to adjust for potential confounders.Results:Baseline characteristics were well-balanced between the two groups. At one-month follow-up, the SGLT2i group showed a significantly greater improvement in LVEF than the control group, with a multivariable-adjusted effect size of 1.92% (95% confidence interval (CI): 0.44\u20133.40%; p = 0.012). Serum uric acid levels were significantly lower in the SGLT2i group than in the control group (p = 0.006). In both groups, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels decreased from baseline to one-month follow-up, with no significant between-group difference. The incidence of adverse events was similar between groups, and no cases of ketoacidosis or severe deterioration in renal function were observed.Conclusion:In hemodynamically stable patients with acute anterior STEMI complicated by HF, early initiation of SGLT2 inhibitors was associated with higher LVEF at 1 month and a trend toward lower uric acid levels, without significant differences in safety outcomes between groups. These preliminary findings suggest potential benefit and warrant confirmation in prospective studies.<\/jats:p>","DOI":"10.31083\/rcm48719","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:17:46Z","timestamp":1788437866000},"source":"Crossref","is-referenced-by-count":0,"title":["Short-Term Efficacy of Early Sodium\u2013Glucose Cotransporter 2 Inhibitor Initiation in Patients With Heart Failure After Acute Anterior Myocardial Infarction"],"prefix":"10.31083","volume":"27","author":[{"given":"Shuli","family":"Bi","sequence":"first","affiliation":[{"name":"School of Medicine, Nankai University, 300071 Tianjin, China"},{"name":"Department of Cardiology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, 300121 Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, 300121 Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, 300121 Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, 300121 Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, 300121 Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6443-9616","authenticated-orcid":true,"given":"Wenqi","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, 300121 Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, 300121 Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Medicine, Nankai University, 300071 Tianjin, China"},{"name":"Department of Cardiology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, 300121 Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuhua","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, 300121 Tianjin, China"},{"name":"The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, 300121 Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Harrington J, Petrie MC, Anker SD, Bhatt DL, Jones WS, Udell JA, et al. Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review. JAMA Cardiology. 2022; 7: 1067\u20131075.","DOI":"10.1001\/jamacardio.2022.2847"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Jen\u010da D, Melenovsk\u00fd V, Stehlik J, Stan\u011bk V, Kettner J, Kautzner J, et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Failure. 2021; 8: 222\u2013237.","DOI":"10.1002\/ehf2.13144"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Li Y, Han YL. Interpretation of 2023 ESC guidelines for the management of acute coronary syndromes. Zhonghua Xin Xue Guan Bing Za Zhi. 2023; 51: 1263\u20131267.  (In Chinese)","DOI":"10.3760\/cma.j.cn112148-20230920-00175"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine. 2019; 380: 347\u2013357.","DOI":"10.1056\/NEJMoa1812389"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine. 2023; 388: 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. The New England Journal of Medicine. 2020; 383: 1413\u20131424.","DOI":"10.1056\/NEJMoa2022190"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England Journal of Medicine. 2021; 385: 1451\u20131461.","DOI":"10.1056\/NEJMoa2107038"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine. 2022; 387: 1089\u20131098.","DOI":"10.1056\/NEJMoa2206286"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evidence. 2024; 3: EVIDoa2300286.","DOI":"10.1056\/EVIDoa2300286"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, et al. Empagliflozin after Acute Myocardial Infarction. The New England Journal of Medicine. 2024; 390: 1455\u20131466.","DOI":"10.1056\/NEJMoa2314051"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC. Cardiovascular Imaging. 2011; 4: 98\u2013108.","DOI":"10.1016\/j.jcmg.2010.10.008"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018; 138: e618\u2013e651.","DOI":"10.1161\/CIR.0000000000000617"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Branch of Cardiovascular Physicians, Chinese Medical Doctor Association, China Cardiovascular Health Alliance, The Expert Consensus Working Group on the Prevention, Treatment of Heart Failure After Myocardial Infarction. 2020 Expert Consensus on the Prevention and Treatment of Heart Failure After Myocardial Infarction. Chinese Circulation Journal. 2020; 35: 1166\u20131180.  (In Chinese)","DOI":"10.3969\/j.issn.1000-3614.2020.12.002"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021; 42: 3599\u20133726.","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. Journal of the American Society of Echocardiography. 2019; 32: 1\u201364.","DOI":"10.1016\/j.echo.2018.06.004"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Austin PC, Steyerberg EW. The number of subjects per variable required in linear regression analyses. Journal of Clinical Epidemiology. 2015; 68: 627\u2013636.","DOI":"10.1016\/j.jclinepi.2014.12.014"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Khan U, Amin AM, Mohamed Taha A, Khlidj Y, M AlBarakat M, Elewidi M, et al. The effect of sodium-glucose co-transporter 2 inhibitors on clinical outcomes after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Future Cardiology. 2025; 21: 177\u2013190.","DOI":"10.1080\/14796678.2025.2464449"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Zhou L, Geng X, Hu Q, Gu J, Chen Y. Effects of dapagliflozin on cardiac function and short-term prognosis of patients with both acute myocardial infarction and type 2 diabetes mellitus. Minerva Cardiology and Angiology. 2024; 72: 292\u2013298.","DOI":"10.23736\/S2724-5683.23.06478-5"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. European Heart Journal. 2022; 43: 4421\u20134432.","DOI":"10.1093\/eurheartj\/ehac494"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Karakasis P, Fragakis N, Kouskouras K, Karamitsos T, Patoulias D, Rizzo M. Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella? Clinical Therapeutics. 2024; 46: 841\u2013850.","DOI":"10.1016\/j.clinthera.2024.06.010"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Hernandez AF, Udell JA, Jones WS, Anker SD, Petrie MC, Harrington J, et al. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. Circulation. 2024; 149: 1627\u20131638.","DOI":"10.1161\/CIRCULATIONAHA.124.069217"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018; 61: 722\u2013726.","DOI":"10.1007\/s00125-017-4509-7"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Sayour AA, Korkmaz-Ic\u00f6z S, Loganathan S, Ruppert M, Sayour VN, Ol\u00e1h A, et al. Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. Journal of Translational Medicine. 2019; 17: 127.","DOI":"10.1186\/s12967-019-1881-8"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radical Biology & Medicine. 2017; 104: 298\u2013310.","DOI":"10.1016\/j.freeradbiomed.2017.01.035"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023; 44: 3627\u20133639.","DOI":"10.1093\/eurheartj\/ehad195"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Hu X, Yang Y, Hu X, Jia X, Liu H, Wei M, et al. Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. Diabetes, Obesity & Metabolism. 2022; 24: 228\u2013238.","DOI":"10.1111\/dom.14570"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Xin Y, Guo Y, Li Y, Ma Y, Li L, Jiang H. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis. Saudi Journal of Biological Sciences. 2019; 26: 421\u2013426.","DOI":"10.1016\/j.sjbs.2018.11.013"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Annals of the Rheumatic Diseases. 2010; 69: 1162\u20131164.","DOI":"10.1136\/ard.2009.122770"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes, Obesity & Metabolism. 2018; 20: 458\u2013462.","DOI":"10.1111\/dom.13101"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"L\u00fcscher BP, Surbek DV, Cl\u00e9men\u00e7on B, Huang X, Albrecht C, Marini C, et al. Different Pharmacological Properties of GLUT9a and GLUT9b: Potential Implications in Preeclampsia. Cellular Physiology and Biochemistry. 2019; 53: 508\u2013517.","DOI":"10.33594\/000000154"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Takata T, Isomoto H. Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control. International Journal of Molecular Sciences. 2021; 22: 4374.","DOI":"10.3390\/ijms22094374"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/8\/10.31083\/RCM48719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:18:26Z","timestamp":1788437906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/8\/10.31083\/RCM48719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2153-8174(26)03618-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm48719","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"48719"}}